Active Ingredient History
Saroglitazar is a drug for the treatment of type 2 diabetes mellitus and dyslipidemia. It is approved for use in India by the Drug Controller General of India. Saroglitazar is indicated for the treatment of diabetic dyslipidemia and hypertriglyceridemia with type 2 diabetes mellitus not controlled by statin therapy. In clinical studies, saroglitazar has demonstrated reduction of triglycerides (TG), LDL cholesterol, VLDL cholesterol, non-HDL cholesterol and an increase in HDL cholesterol a characteristic hallmark of atherogenic diabetic dyslipidemia (ADD). It has also shown anti-diabetic medication properties by reducing the fasting plasma glucose and HBA1c in diabetes patients. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Diabetes Mellitus, Type 2 (Phase 4)
Dyslipidemias (Phase 4)
Fatty Liver (Phase 3)
Fibrosis (Phase 2)
Healthy Volunteers (Phase 1)
Kidney Failure, Chronic (Phase 1)
Liver Cirrhosis, Biliary (Phase 2/Phase 3)
Liver Diseases (Phase 1)
Liver Transplantation (Phase 2)
Metabolic Syndrome (Phase 4)
Non-alcoholic Fatty Liver Disease (Phase 4)
Obesity (Phase 4)
Polycystic Ovary Syndrome (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue